Salus

Founded in 2020 and based in Shenzhen, China, Salus is a biotech medical company that focuses on R&D of sequencing and spatial omics platforms. It cooperated with universities and enterprises such as Sun Yat-sen University and Shenzhen Institute of Synthetic Biology. Luyang Zhao, the founder and the CEO of the company, was a senior VP at QIELOU Capital and a senior analyst at GTJA Investment Group. In October 2025, Salus raised a series B1 funding from new investor Amoy Diagnostics Co.

, Ltd. The company's main products include Sequencers, Spatial Omics Scopes, and Kits and Reagents. Sequencers provide throughput, sequencing and data export services based on Salus microarray, enzyme and chemical reagent technology. Its products can be used in non-invasive prenatal genetic testing, microbial testing, tumor diagnosis and treatment, assisted reproduction and other fields.

The company will use the funding for the R&D and registration filing of gene sequencing platform and spatial genomics products.